Cargando…

Drug Delivery Systems Based on Pluronic Micelles with Antimicrobial Activity

Bacterial oral diseases are chronic, and, therefore, require appropriate treatment, which involves various forms of administration and dosing of the drug. However, multimicrobial resistance is an increasing issue, which affects the global health system. In the present study, a commercial amphiphilic...

Descripción completa

Detalles Bibliográficos
Autores principales: Popovici, Corina, Popa, Marcel, Sunel, Valeriu, Atanase, Leonard Ionut, Ichim, Daniela Luminita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331063/
https://www.ncbi.nlm.nih.gov/pubmed/35893968
http://dx.doi.org/10.3390/polym14153007
_version_ 1784758312377516032
author Popovici, Corina
Popa, Marcel
Sunel, Valeriu
Atanase, Leonard Ionut
Ichim, Daniela Luminita
author_facet Popovici, Corina
Popa, Marcel
Sunel, Valeriu
Atanase, Leonard Ionut
Ichim, Daniela Luminita
author_sort Popovici, Corina
collection PubMed
description Bacterial oral diseases are chronic, and, therefore, require appropriate treatment, which involves various forms of administration and dosing of the drug. However, multimicrobial resistance is an increasing issue, which affects the global health system. In the present study, a commercial amphiphilic copolymer, Pluronic F127, was used for the encapsulation of 1-(5′-nitrobenzimidazole-2′-yl-sulphonyl-acetyl)-4-aryl-thiosemicarbazide, which is an original active pharmaceutical ingredient (API) previously synthesized and characterized by our group, at different copolymer/API weight ratios. The obtained micellar systems, with sizes around 20 nm, were stable during 30 days of storage at 4 °C, without a major increase of the Z-average sizes. As expected, the drug encapsulation and loading efficiencies varied with the copolymer/API ratio, the highest values of 84.8 and 11.1%, respectively being determined for the F127/API = 10/1 ratio. Moreover, in vitro biological tests have demonstrated that the obtained polymeric micelles (PMs) are both hemocompatible and cytocompatible. Furthermore, enhanced inhibition zones of 36 and 20 mm were observed for the sample F127/API = 2/1 against S. aureus and E. coli, respectively. Based on these encouraging results, it can be admitted that these micellar systems can be an efficient alternative for the treatment of bacterial oral diseases, being suitable either by injection or by a topical administration.
format Online
Article
Text
id pubmed-9331063
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93310632022-07-29 Drug Delivery Systems Based on Pluronic Micelles with Antimicrobial Activity Popovici, Corina Popa, Marcel Sunel, Valeriu Atanase, Leonard Ionut Ichim, Daniela Luminita Polymers (Basel) Article Bacterial oral diseases are chronic, and, therefore, require appropriate treatment, which involves various forms of administration and dosing of the drug. However, multimicrobial resistance is an increasing issue, which affects the global health system. In the present study, a commercial amphiphilic copolymer, Pluronic F127, was used for the encapsulation of 1-(5′-nitrobenzimidazole-2′-yl-sulphonyl-acetyl)-4-aryl-thiosemicarbazide, which is an original active pharmaceutical ingredient (API) previously synthesized and characterized by our group, at different copolymer/API weight ratios. The obtained micellar systems, with sizes around 20 nm, were stable during 30 days of storage at 4 °C, without a major increase of the Z-average sizes. As expected, the drug encapsulation and loading efficiencies varied with the copolymer/API ratio, the highest values of 84.8 and 11.1%, respectively being determined for the F127/API = 10/1 ratio. Moreover, in vitro biological tests have demonstrated that the obtained polymeric micelles (PMs) are both hemocompatible and cytocompatible. Furthermore, enhanced inhibition zones of 36 and 20 mm were observed for the sample F127/API = 2/1 against S. aureus and E. coli, respectively. Based on these encouraging results, it can be admitted that these micellar systems can be an efficient alternative for the treatment of bacterial oral diseases, being suitable either by injection or by a topical administration. MDPI 2022-07-25 /pmc/articles/PMC9331063/ /pubmed/35893968 http://dx.doi.org/10.3390/polym14153007 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Popovici, Corina
Popa, Marcel
Sunel, Valeriu
Atanase, Leonard Ionut
Ichim, Daniela Luminita
Drug Delivery Systems Based on Pluronic Micelles with Antimicrobial Activity
title Drug Delivery Systems Based on Pluronic Micelles with Antimicrobial Activity
title_full Drug Delivery Systems Based on Pluronic Micelles with Antimicrobial Activity
title_fullStr Drug Delivery Systems Based on Pluronic Micelles with Antimicrobial Activity
title_full_unstemmed Drug Delivery Systems Based on Pluronic Micelles with Antimicrobial Activity
title_short Drug Delivery Systems Based on Pluronic Micelles with Antimicrobial Activity
title_sort drug delivery systems based on pluronic micelles with antimicrobial activity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331063/
https://www.ncbi.nlm.nih.gov/pubmed/35893968
http://dx.doi.org/10.3390/polym14153007
work_keys_str_mv AT popovicicorina drugdeliverysystemsbasedonpluronicmicelleswithantimicrobialactivity
AT popamarcel drugdeliverysystemsbasedonpluronicmicelleswithantimicrobialactivity
AT sunelvaleriu drugdeliverysystemsbasedonpluronicmicelleswithantimicrobialactivity
AT atanaseleonardionut drugdeliverysystemsbasedonpluronicmicelleswithantimicrobialactivity
AT ichimdanielaluminita drugdeliverysystemsbasedonpluronicmicelleswithantimicrobialactivity